7189-18-6

Basic information

• Product Name: 1-(4-chlorobenzyl)-2-(chloromethyl)-1H-benzo[d]imidazole
• Synonyms: 1-(4-chlorobenzyl)-2-(chloromethyl)-1H-benzo[d]imidazole
• CAS NO: 7189-18-6
• Molecular Weight: 291.18
• Mol File: 7189-18-6.mol
• Article Data: 6

Chemical Properties

• Melting Point: 117 °C (decomp)
• Boiling Point: 469.8±35.0 °C(Predicted)
• Density: 1.30±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 1-(4-chlorobenzyl)-2-(chloromethyl)-1H-benzo[d]imidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-chlorobenzyl)-2-(chloromethyl)-1H-benzo[d]imidazole(7189-18-6)
• EPA Substance Registry System: 1-(4-chlorobenzyl)-2-(chloromethyl)-1H-benzo[d]imidazole(7189-18-6)

Safety Data

• Hazardous Substances Data: 7189-18-6(Hazardous Substances Data)

Usage

General Description

1-(4-chlorobenzyl)-2-(chloromethyl)-1H-benzo[d]imidazole is a chemical compound with the molecular formula C16H13Cl2N2. It is an organic compound that belongs to the class of benzimidazoles, which are heterocyclic aromatic compounds. 1-(4-chlorobenzyl)-2-(chloromethyl)-1H-benzo[d]imidazole contains both chlorobenzyl and chloromethyl groups, which make it potentially useful in various chemical reactions and organic synthesis. It has been identified as a potential pharmaceutical intermediate and may have applications in the development of new drugs. Further research and analysis are needed to fully understand its properties and potential uses in various industries.

Upstream product

• 5729-18-0 N-(p-Chlorophenylmethyl)-2-amino aniline 
• 79-11-8 chloroacetic acid 
• 622-95-7 4-chlorobenzyl bromide 
• 33809-91-5 (1H-benzo[d]imidazol-2-yl)methyl acetate 
• 7187-31-7 (1-(4-chlorobenzyl)-1H-benzo[d]imidazol-2-yl)methanol 
• 104-83-6 1-Chloro-4-(chloromethyl)benzene 
• 95-54-5 1,2-diamino-benzene 
• 5822-16-2 N-(p-Chlorobenzyl)-2-nitro aniline 

Downstream Products

• 442-52-4 clemizole 

Relevant articles and documents

Design, Synthesis and Antimicrobial Evaluation of Novel Benzimidazole-incorporated Naphthalimide Derivatives as Salmonella typhimurium DNA Intercalators, and Combination Researches

Objective: A series of novel benzimidazole-incorporated naphthalimide derivatives were designed and prepared in an effort to overcome the increasing antibiotic resistance. Methods: The target novel benzimidazole-incorporated naphthalimide derivatives were synthesized from commercial 4-bromo-1,8-naphthalic anhydride and o-phenylene diamine by aminolysis, N-alkylation and so on. The antimicrobial activity of the synthesized compounds was evaluated in vitro by a two-fold serial dilution technique. The interaction of compound 10g with Salmonella typhimuri-um DNA was studied using UV-vis spectroscopic methods. Results: Compound 10g bearing a 2,4-dichlorobenzyl moiety exhibited the best antimicrobial activities in this series relatively; especially, it exhibited comparable activity against Salmonella typhi-murium in comparison with the reference drug Norfloxacin (MIC = 4 μg/mL). Further research showed that compound 10g could effectively intercalate into the Salmonella typhimurium DNA to form the 10g–DNA complex, which might correlate with the inhibitory activity. Molecular docking results demonstrated that naphthalimide compound 10g could interact with base-pairs of DNA hex-amer duplex by π–π stacking. Additionally, the combination of the strong active compound with clinical drugs exhibited better antimicrobial efficiency with less dosage and broader antimicrobial spectrum than the separate use of them alone. Notably, these combined systems were more sensitive to Fluconazole-insensitive M. ruber. Conclusion: This work provides a promising starting point to optimize the structures of benzimidaz-ole-incorporated naphthalimide derivatives as potent antimicrobial agents.

Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove

A novel series of purine benzimidazole hybrids were designed and synthesized for the first time with the aim to circumvent the increasing antibiotic resistance. Hexyl appended hybrid 3c gave potent activities against most of the tested bacteria and fungi especially against multidrug-resistant strains Staphylococcus aureus (MIC = 4 μg/mL). Structure-activity relationships revealed that the benzimidazole fragment at the 9-position of purine played an important role in exerting potentially antibacterial activity. Both cell toxicity and ROS generation assays indicated that the purine derivative 3c showed low cytotoxicity and could be used as a safe agent. Molecular modeling suggested that hybrid 3c could bind with the residues of Topo IA through hydrogen bonds and electrostatic interactions. Quantum chemical studies were also performed on the target compound 3c to understand the structural features essential for activity. The active molecule 3c could effectively interact with S. aureus DNA to form 3c–DNA complex through groove binding mode, which might block DNA replication to display their powerful antimicrobial activity.

BENZIMIDAZOLE MODULATORS OF H1 RECEPTOR AND/OR NS4B PROTEIN ACTIVITY

The present invention relates to new benzimidazole modulators of H1 receptor activity and/or inhibitors of NS4B protein activity, pharmaceutical compositions thereof, and methods of use thereof formula (I).